Personal Statement
Sanjiv Sharma is currently a Senior Lecturer in Infectious Diseases and Antimicrobial Resistance in the David Price Evans Global Health and Infectious Diseases Group at the University of Liverpool's Department of Pharmacology & Therapeutics within the Institute of Systems, Molecular and Integrative Biology. He is a Fellow of the Royal Society of Chemistry and the Higher Education Academy.

He trained as a chemist, holding degrees from Dr. Hari Singh Gour University, Sagar, India, and completed his PhD as part of an Indo-European Communities Joint research project in collaboration with the University of Amsterdam and the Regional Research Laboratory (CSIR), India. His research focuses on the development of innovative biosensing and diagnostic technologies, particularly subdermal wearable biosensors, point-of-care devices, and microfluidic diagnostics. He has made significant contributions to the fields of electrochemical biosensors, lab-on-a-chip systems, and transdermal drug and vaccine delivery devices.

He has been instrumental in pioneering low-cost, transdermal biosensing devices, successfully advancing them from the lab to clinical settings. His work has garnered over 3000 citations, with an h-index of 24, and he has published over 85 research articles, conference proceedings, and book chapters. His contributions to biomedical engineering have been recognized through various honors, including the Chevening Technology Fellowship from the British Foreign Office and his election as a Fellow of the Royal Society of Chemistry.

In addition to his academic research, he has been actively involved in several Research Council Committees and has collaborated with various industry partners, including his role as Principal Investigator on multiple high-profile grants. His work has been featured in media outlets such as the BBC, highlighting the impact of his research on public health.

He is also a member of the Royal Society’s Newton International Fellowships Committee and the UKRI Interdisciplinary Assessment College, and has held visiting academic positions, further underscoring his commitment to advancing research and innovation in his field.

Research Overview

Overview

Research in our group is centered on the development of innovative diagnostic and therapeutic technologies, with a particular emphasis on creating solutions that are accessible and effective in low-resource settings. Our key focus areas include:

Subdermal Wearable Biosensors: We are developing minimally invasive sensors designed for continuous monitoring of physiological and biochemical markers in real-time. These devices are tailored for applications in personalized healthcare, with a special focus on making them affordable and practical for use in low-resource environments.

Point-of-Care Devices: Our work in point-of-care diagnostics is aimed at creating portable, low-cost devices that deliver rapid and accurate results. These technologies are being developed for a range of applications, including clinical diagnostics, remote healthcare, and public health monitoring, particularly in settings where resources are limited.

Electrochemical Biosensors: We are designing and fabricating electrochemical biosensors that utilize various bioreceptors, including enzymes, aptamers, and peptide receptors. These sensors are optimized for the detection of critical biomolecules, such as glucose and pathogens, with applications in both clinical and environmental contexts, and are being developed with cost-effectiveness in mind.

Microfluidic Diagnostics and Lab-on-a-Chip: Our research includes the integration of microfluidic systems with biosensing technologies to create compact, efficient diagnostic devices. These lab-on-a-chip platforms enable multiplexed testing and are designed to be affordable and accessible, offering powerful tools for rapid and high-throughput analysis in both clinical and research environments.

Transdermal and Intradermal Therapeutic Delivery: We are innovating in the field of drug and vaccine delivery by developing microneedle-based devices for transdermal and intradermal administration. These technologies aim to improve patient comfort and adherence while ensuring cost-effectiveness for broader implementation, especially in resource-constrained areas.

Multiplexed Ultrasensitive Point-of-Care Testing: Our team is advancing the capabilities of point-of-care testing through the development of multiplexed assays that can detect multiple analytes simultaneously with high sensitivity. This approach is key to enhancing the diagnostic power and efficiency of point-of-care devices, with an emphasis on affordability and scalability for widespread use.